Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Abstract

Previous methods for biobanking prostate tissue, following radical prostatectomy, generally involved random sampling. In order to increase efficiency, and enable a greater range of downstream applications, a more targeted method of sampling prostate tissue was developed. Here we use both magnetic resonance imaging (MRI) and biopsy data to target specific areas of the organ for sampling. The method involves use of a previously published prostate slicing device which removes a 5 mm transverse slice from a predetermined region of the prostate, followed by the removal of 6 mm punch biopsies from predetermined areas of this slice. These samples can be stored frozen or fixed for biobanking purposes, or used fresh immediately with 70% confidence of tumor content, as compared with 10% confidence from the random sampling approach. This enables the use of all standard downstream techniques such as genomics, proteomics or histological work, but also work that requires fresh tissue such as live tissue imaging or ex vivo culture.

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

“…Matched tumour and benign human prostate tissue was collected from patients who had provided informed consent under UCL/UCLH Biobank ethics (REC 15/YH/0311), and sampled as per the PEOPLE method 27 , 42 . Tissue was cultured ex vivo and treated with AZD-1208, BEZ235, a combination of AZD-1208 and BEZ235, AUM302 or untreated, using the gelatin sponge method for 72 h 27 .…”

“…Human prostate tissue was cultured ex vivo following Magnetic Resonance Imaging (MRI) guided tumour targeting 27,28 . Four patients were recruited for this study, all of whom underwent radical prostatectomy and had Gleason ≥ 3 + 4, ≥ Likert 3 disease ( Supplementary Table S5).…”